Skip to Main Content

Paper Details

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
JAMA Oncol
474
2019
Hypothyroidism, Nivolumab, PD-1, PD-L1, anemia, aspartate, aspartate aminotransferase, cancer, diarrhea, fatigue, hyperthyroidism, patients, pembrolizumab, programmed cell death ligand 1, pruritus
Author NameAffiliation
Chan ShenDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center
Katharine A PriceMayo Clinic
Lance C PagliaroMayo Clinic
  • 1 - 3

Datasets

Dataset
Description
Source Link
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
Release 1.2